Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-24-025501

CHIEF FINANCIAL OFFICER sold 814 shares at $30.00 ($24,422)

  • CHIEF FINANCIAL OFFICER acquired 814 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Hohl Benjamin CHIEF FINANCIAL OFFICER 2024-10-18 Option exercise 10b5-1 +814 $2.48 $2,019 814 D: show line 1 in the form
Hohl Benjamin CHIEF FINANCIAL OFFICER 2024-10-18 Sale 10b5-1 −814 $30.00 $24,422 0 D: show line 2 in the form
Open-market sales · 814 sh · avg $30.00 · $24,422

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Hohl Benjamin CHIEF FINANCIAL OFFICER 2024-10-18 Option exercise · Stock Option (right to buy) 10b5-1 −814 180,056 D: show line 3 in the form
Loading xslF345X05/form4-10222024_081055.xml…